Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-09-30
Buyer: Oslo Universitetssykehus HF (hovedenhet)
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 19203412 NOK
Award criteria: The most economic tender

Technical requirements: The newborn screening at BAR, OUS offers testing for all newborn babies in Norway for 25 serious, congenital conditions. Four of the analyses are carried out with immunoassay and enzymatic analyses. This are 17 a-hydroxyprogesterone, thyroid-stimulating hormone, immunoactive trypsinogen and biotinidase activity. In addition it will be relevant to have an option for analyses of thyroxin and GALT1 for an expanded offer and research.
The newborn screening depends on a fully automated, flexible instrument with an option for continual sample application for all these analyses, and only one technological platform. The technology and analyses must also be documented in the CDC QX programme for newborn screening. The instrument must also be able to communicate with Panthera Punchere for data exchange.
The newborn screening at BAR, OUS offers testing for all newborn babies in Norway for serious, congenital conditions. Four of the analyses are carried out with immunoassay and enzymatic analyses. This are 17 a-hydroxyprogesterone, thyroid-stimulating hormone, immunoactive trypsinogen and biotinidase activity. In addition it will be relevant to have an option for analyses of thyroxin and GALT1 for an expanded offer and research.
The newborn screening depends on a fully automated, flexible instrument with an option for continual sample application for all these analyses, and only one technological platform. The technology and analyses must also be documented in the CDC QX programme for newborn screening. The instrument must also be able to communicate with Panthera Punchere for data exchange.
The newborn screening at BAR, OUS offers testing for all newborn babies in Norway for serious, congenital conditions. Four of the analyses are carried out with immunoassay and enzymatic analyses. This are 17 a-hydroxyprogesterone, thyroid-stimulating hormone, immunoactive trypsinogen and biotinidase activity. In addition it will be relevant to have an option for analyses of thyroxin and GALT1 for an expanded offer and research.
The newborn screening depends on a fully automated, flexible instrument with an option for continual sample application for all these analyses, and only one technological platform. The technology and analyses must also be documented in the CDC QX programme for newborn screening. The instrument must also be able to communicate with Panthera Punchere for data exchange.
We are of the opinion that Perkin Elmer is the only supplier that, due to technical reasons, can deliver an instrument for immunoassay and enzymatic analyses (GSP) in accordance with the requirements. The voluntary ex-ante transparency notice is pursuant to the public procurement regulations § 21-5.
The terms in FOA § 13-4 (2) and 13-1 (5) are deemed to be fulfilled as well as the value of the full reagent contract and service contract for the instrument's lifetime.


Winner: PerkinElmer Norge AS
Award value: 19203412